Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

Affiliations

¹ GEICO and MD Anderson Cancer Center Spain, Madrid, Spain. Electronic address: agonzalezm@seom.org.
² GINECO and Institut Claudius Regaud, Toulouse, France.
³ NSGO and Uppsala University Hospital, Uppsala, Sweden.
⁴ Moscow Oncology Hospital No. 62, Moscow, Russian Federation.
⁵ The Royal Marsden Hospital, London, UK.
⁶ Università Cattolica Roma, Rome, Italy.
⁷ Vall d'Hebron University Hospital, Barcelona, Spain.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ MITO and Department of Urology and Gynecology, Istituto Nazionale Tumori Fondazione G. Pascale, IRCCS, Naples, Italy.

Comment

Antonio Gonzalez-Martin et al. Eur J Cancer. 2014 Mar.

. 2014 Mar;50(4):862-3.

doi: 10.1016/j.ejca.2013.12.001. Epub 2014 Jan 10.

¹ GEICO and MD Anderson Cancer Center Spain, Madrid, Spain. Electronic address: agonzalezm@seom.org.
² GINECO and Institut Claudius Regaud, Toulouse, France.
³ NSGO and Uppsala University Hospital, Uppsala, Sweden.
⁴ Moscow Oncology Hospital No. 62, Moscow, Russian Federation.
⁵ The Royal Marsden Hospital, London, UK.
⁶ Università Cattolica Roma, Rome, Italy.
⁷ Vall d'Hebron University Hospital, Barcelona, Spain.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ MITO and Department of Urology and Gynecology, Istituto Nazionale Tumori Fondazione G. Pascale, IRCCS, Naples, Italy.

No abstract available

Comment on

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.